Sherwin Sattarzadeh

Mr. Sattarzadeh joined Blueprint Medicines in September 2015 as Senior Director, Head of Regulatory Affairs, and successfully led regulatory strategy and execution from the initiation of development to the U.S. and EU approvals of the company’s two marketed medicines. He was promoted to Vice President in February 2018 and transitioned to a Chief of Staff role in March 2020, where he has helped the company navigate a time of significant growth during the global pandemic. Prior to joining Blueprint Medicines, Mr. Sattarzadeh held roles of increasing responsibility in the regulatory affairs teams of Genzyme, Titan Pharmaceuticals and Genelabs Technologies. Mr. Sattarzadeh earned a B.Sc. in Chemistry from the University of British Columbia, and an MBA in Finance from Boston University.